SCHEMBL164043

SCHEMBL164043

CC(C)(C)C1CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1704716 1.00
SCHEMBL1705094 1.00
Hydrochloric Acid SCHEMBL5241681 0.97 KDM4E (0.42)
Methane SCHEMBL28330275 0.97 KDM4E (0.38)
SCHEMBL10326679 0.92 CYP2D6 (0.34)
SCHEMBL3229383 0.92 CYP2D6 (0.34)
SCHEMBL1547510 0.92 CYP2D6 (0.34)
SCHEMBL24922624 0.90 CYP2D6 (0.33)
SCHEMBL22260036 0.90 CYP2D6 (0.33)
SCHEMBL797872 0.90 CYP2D6 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 495 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013177269-A2 ZIRCONIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) 2013-11-28 WO claimed
WO-2013177284-A1 HAFNIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) 2013-11-28 WO claimed
WO-2013177292-A1 TITANIUM-CONTAINING PRECURSORS FOR VAPOR DEPOSITION L'AIR LIQUIDE, SOCIETE ANONYME POUR L'ETUDE ET L'EXPLOITATION DES PROCEDES GEORGES CLAUDE (FR) 2013-11-28 WO claimed
CN-112533902-B Composition comprising a nitroxide inhibitor, a quinone methide blocker and an amine stabilizer to inhibit polymerization of monomers 埃科莱布美国股份有限公司 2025-03-14 CN disclosed
CN-114478520-B Bcl-2 protein apoptosis inducer and application thereof 杭州和正医药有限公司 2025-01-10 CN disclosed
US-20240216515-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2024-07-04 US disclosed
US-20240207178-A1 COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM 2024-06-27 US disclosed
US-20240065261-A1 PENETRATING CRYOPROTECTION AGENTS AND METHODS OF MAKING AND USING SAME UNIV NEW YORK STATE RES FOUND (US) 2024-02-29 US disclosed
US-20240065261-A1 PENETRATING CRYOPROTECTION AGENTS AND METHODS OF MAKING AND USING SAME UNIV NEW YORK STATE RES FOUND (US) 2024-02-29 US disclosed
US-20240018156-A1 SPIROCYCLIC COMPOUNDS C4 THERAPEUTICS, INC. (US) 2024-01-18 US disclosed
US-11873316-B2 Compositions and methods for phosphoramidite and oligonucleotide synthesis WAVE LIFE SCIENCES LTD. (SG) 2024-01-16 US disclosed
US-7244735-B2 Heterocyclic protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INC. (US) 2007-07-17 US disclosed
US-7244738-B2 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists ROCHE PALO ALTO LLC (US) 2007-07-17 US disclosed
US-7244738-B2 Arylamine-substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists ROCHE PALO ALTO LLC (US) 2007-07-17 US disclosed
US-20070155716-A1 HCV INHIBITING BI-CYCLIC PYRIMIDINES TIBOTEC PHARMACEUTICALS LTD. (IE) 2007-07-05 US disclosed
WO-2007005534-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-01-11 WO disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
US-20070004675-A1 Inhibitors of VEGF receptor and HGF receptor signaling METHYLGENE, INC. 2007-01-04 US disclosed
WO-2005049023-A1 GLYT1 TRANSPORTER INHIBITORS GLAXO GROUP LIMITED (GB) 2005-06-02 WO disclosed
WO-2003055478-A1 GLYT1 TRANSPORTER INHIBITORS AND USES THEREOF IN TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS SMITHKLINE BEECHAM P.L.C. (GB) 2003-07-10 WO disclosed